Targeting RET mutation in medullary thyroid cancer

References

• 1. Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Exp. Revi. Anticanc. Ther. 8(4), 625–632 (2008).
  Medline CASGoogle Scholar
• 2. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat. Clin. Pract. Endocrinol. Metab. 4(1), 22–32 (2008).
  Medline CASGoogle Scholar
• 3. Callejo IP, Brito JA, Zagalo CM, Santos JR. Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival. Clin. Transl. Oncol. 8(6), 435–443 (2006).
  MedlineGoogle Scholar
• 4. NCCN (National comprehensive cancer network) Thyroid Carcinoma - NCCN Guidelines Version 4.2023. www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
  Google Scholar
• 5. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134 (2012).
  Medline CASGoogle Scholar
• 6. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639 (2013).
  Medline CASGoogle Scholar
• 7. Kouvaraki MA, Shapiro SE, Perrier ND et al. RET Proto-oncogene: a review and update of genotype–phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6), 531–544 (2005).
  Medline CASGoogle Scholar
• 8. Xu B, Viswanathan K, Ahadi MS et al. Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study. Thyroid doi: 10.1089/thy.2023.0279 (2023).
  Google Scholar
• 9. Ciampi R, Romei C, Ramone T et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. IScience 20, 324–336 (2019).
  Medline CASGoogle Scholar
• 10. Romei C, Casella F, Tacito A et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J. Med. Genet. 53(11), 729–734 (2016).
  Medline CASGoogle Scholar
• 11. Hadoux J, Elisei R, Brose MS et al. Phase III trial of selpercatinib in advanced RET -mutant medullary thyroid cancer. N. Engl. J. Med. 389(20), 1851–1861 (2023).
  Medline CASGoogle Scholar
• 12. Subbiah V, Hu MI, Wirth LJ et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW), a multi-cohort, open-label, registrational, Phase I/2 study. Lancet Diab. Endocrinol. 9(8), 491–501 (2021).
  Medline CASGoogle Scholar
• 13. Wirth LJ, Sherman E, Robinson B et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383(9), 825–835 (2020).
  Medline CASGoogle Scholar
• 14. ESMO. EMA recommends extension of therapeutic indications for selpercatinib. www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-selpercatinib
  Google Scholar
• 15. Research C for DE and. FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. FDA (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions
  Google Scholar